<p>G1 (1x10<sup>6</sup>), G3 (1x10<sup>6</sup>), or del<i>ζ</i> (8x10<sup>4</sup>)-T-cells were stimulated in 7-day cycles with irradiated CD32-80-137L (A. left panel), CD32-80-137L-EGFRVIIIΔ654 (B. middle panel) (both preloaded with anti-CD3, and anti-CD28), or EGFRVIIIΔ654aAPCs (C. right panel) at a 2:1 ratio. CAR T-cells were then exposed to U87-EGFRvIII tumor cells and supernatants were collected 24 hours thereafter. IFN-<i>γ</i> (solid black bar), and IL-2 (grey bar) expression was measured by ELISA. Significant difference in IFN-<i>γ</i> expression was observed in G3 CAR T-cells when cocultured with CD32-80-137L aAPC compared to delζ CAR T-cells (F<sub>2,2</sub> = 8717, <i>p</i> = .0002), as well as in G1 CAR-T cells compared to del<i...
<p>CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated by flow cytometry before and afte...
<p>(A) Data from CRA shows inhibition of tumor cell lysis in CD19<sup>+</sup> EL4 cells when CD19-sp...
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however,...
<p>Culture supernatants were collected 24h after stimulation at day 1 (start) and at endpoint (end)....
<p>(<b>a</b>) Expression of CARs (αerbB2-CD28ζ: 57.99±12.66, αerbB2-DAP10ζCD27: 66.38±22.90. N = 3± ...
<p>(A) Plots represent CAR transduction efficiencies in primary T cells, measured by flow cytometry ...
<p>Proliferation was determined each week through cell count prior to addition of B cells. The Figur...
<p>At day 29 of co-culture with AaPC/IL2/IL-21, CAR<sup>+</sup> T cells were co-cultured for 6 hours...
Background aims: Chimeric antigen receptor (CAR) T cells are a novel immunotherapy for cancer. To ac...
© 2020 Practical Medicine Publishing House. All rights reserved. Background. Cytokines are considere...
<p>(a) Overnight co-culture experiments using non transduced (NT), CAR.CD33, or ΔCD19 sel. iC9-CAR.C...
<p>Lineage (A; CD3+ CD8+), exhaustion phenotype (B; PD-1+ Tim-3+) and memory/effector status (C) wer...
<p>(A) Expression of CD19RCD28 CAR on T cells day after electroporation (culture day 1) and after 28...
<p>(A)Short term biophotonic cytolysis assay. Seven days after nucleofection of PBMCs with G1-EGFRvI...
Supplementary Figure S10. A) Overview of the CAR-T production process. B) Expansion of the CAR-T pro...
<p>CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated by flow cytometry before and afte...
<p>(A) Data from CRA shows inhibition of tumor cell lysis in CD19<sup>+</sup> EL4 cells when CD19-sp...
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however,...
<p>Culture supernatants were collected 24h after stimulation at day 1 (start) and at endpoint (end)....
<p>(<b>a</b>) Expression of CARs (αerbB2-CD28ζ: 57.99±12.66, αerbB2-DAP10ζCD27: 66.38±22.90. N = 3± ...
<p>(A) Plots represent CAR transduction efficiencies in primary T cells, measured by flow cytometry ...
<p>Proliferation was determined each week through cell count prior to addition of B cells. The Figur...
<p>At day 29 of co-culture with AaPC/IL2/IL-21, CAR<sup>+</sup> T cells were co-cultured for 6 hours...
Background aims: Chimeric antigen receptor (CAR) T cells are a novel immunotherapy for cancer. To ac...
© 2020 Practical Medicine Publishing House. All rights reserved. Background. Cytokines are considere...
<p>(a) Overnight co-culture experiments using non transduced (NT), CAR.CD33, or ΔCD19 sel. iC9-CAR.C...
<p>Lineage (A; CD3+ CD8+), exhaustion phenotype (B; PD-1+ Tim-3+) and memory/effector status (C) wer...
<p>(A) Expression of CD19RCD28 CAR on T cells day after electroporation (culture day 1) and after 28...
<p>(A)Short term biophotonic cytolysis assay. Seven days after nucleofection of PBMCs with G1-EGFRvI...
Supplementary Figure S10. A) Overview of the CAR-T production process. B) Expansion of the CAR-T pro...
<p>CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated by flow cytometry before and afte...
<p>(A) Data from CRA shows inhibition of tumor cell lysis in CD19<sup>+</sup> EL4 cells when CD19-sp...
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however,...